Histone deacetylase 6 as a novel promising target to treat cardiovascular disease
Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocar...
Gespeichert in:
| Veröffentlicht in: | Cancer innovation (Print) 2024-06, Vol.3 (3), p.e114-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e114 |
| container_title | Cancer innovation (Print) |
| container_volume | 3 |
| creator | Wu, Ya‐Xi Li, Bing‐Qian Yu, Xiao‐Qian Liu, Yu‐Lin Chui, Rui‐Hao Sun, Kai Geng, Dian‐Guang Ma, Li‐Ying |
| description | Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease.
HDAC6 have been found to be a key protein in the tumor–cardiovascular association. HDAC6 inhibitors may have important moderating effects in various types of cardiovascular diseases. HDAC6 inhibitors alone or in combination with other agents have shown promising prospects in the treatment of cardiovascular disease. |
| doi_str_mv | 10.1002/cai2.114 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3074136984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3074136984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2464-c1fa09301b6e1c0054bfc8ea54b9b895f73dd1bff590bbeb1211e6068136c9673</originalsourceid><addsrcrecordid>eNp1kM1KAzEUhYMoVmrBJ5As3UzNnb8ky1LUFgqC6DpkMndKZDpTk7TSt_FZfDJTWuvK1bmL7x4OHyE3wMbAWHpvtE3HAPkZuUo5Z4kEkZ2fbgkDMvL-nUVUAgjBL8kgEzLnvOBX5GVmfeg7pDVqg2HXao-0_P7Snmra9Vts6dr1K-ttt6RBuyUGGnoaHOpAjXa17bfam02rHa2tx_h-TS4a3XocHXNI3h4fXqezZPH8NJ9OFolJ8zJPDDSayYxBVSIYxoq8aoxAHVNWQhYNz-oaqqYpJKsqrCAFwJKVArLSyJJnQ3J36I0DPzbog4ozDbat7rDfeJUxnkdWivwPNa733mGj1s6utNspYGovUe0lqigxorfH1k21wvoE_iqLQHIAPm2Lu3-L1HQyT_eFPwave0E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3074136984</pqid></control><display><type>article</type><title>Histone deacetylase 6 as a novel promising target to treat cardiovascular disease</title><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wu, Ya‐Xi ; Li, Bing‐Qian ; Yu, Xiao‐Qian ; Liu, Yu‐Lin ; Chui, Rui‐Hao ; Sun, Kai ; Geng, Dian‐Guang ; Ma, Li‐Ying</creator><creatorcontrib>Wu, Ya‐Xi ; Li, Bing‐Qian ; Yu, Xiao‐Qian ; Liu, Yu‐Lin ; Chui, Rui‐Hao ; Sun, Kai ; Geng, Dian‐Guang ; Ma, Li‐Ying</creatorcontrib><description>Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease.
HDAC6 have been found to be a key protein in the tumor–cardiovascular association. HDAC6 inhibitors may have important moderating effects in various types of cardiovascular diseases. HDAC6 inhibitors alone or in combination with other agents have shown promising prospects in the treatment of cardiovascular disease.</description><identifier>ISSN: 2770-9191</identifier><identifier>ISSN: 2770-9183</identifier><identifier>EISSN: 2770-9183</identifier><identifier>DOI: 10.1002/cai2.114</identifier><identifier>PMID: 38947757</identifier><language>eng</language><publisher>England</publisher><subject>cardiovascular disease ; histone deacetylase 6 ; inhibitor</subject><ispartof>Cancer innovation (Print), 2024-06, Vol.3 (3), p.e114-n/a</ispartof><rights>2024 The Authors. published by John Wiley & Sons Ltd. on behalf of Tsinghua University Press.</rights><rights>2024 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on behalf of Tsinghua University Press.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2464-c1fa09301b6e1c0054bfc8ea54b9b895f73dd1bff590bbeb1211e6068136c9673</cites><orcidid>0000-0002-7186-8259</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcai2.114$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcai2.114$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,864,11561,27923,27924,46051,46475</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38947757$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Ya‐Xi</creatorcontrib><creatorcontrib>Li, Bing‐Qian</creatorcontrib><creatorcontrib>Yu, Xiao‐Qian</creatorcontrib><creatorcontrib>Liu, Yu‐Lin</creatorcontrib><creatorcontrib>Chui, Rui‐Hao</creatorcontrib><creatorcontrib>Sun, Kai</creatorcontrib><creatorcontrib>Geng, Dian‐Guang</creatorcontrib><creatorcontrib>Ma, Li‐Ying</creatorcontrib><title>Histone deacetylase 6 as a novel promising target to treat cardiovascular disease</title><title>Cancer innovation (Print)</title><addtitle>Cancer Innov</addtitle><description>Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease.
HDAC6 have been found to be a key protein in the tumor–cardiovascular association. HDAC6 inhibitors may have important moderating effects in various types of cardiovascular diseases. HDAC6 inhibitors alone or in combination with other agents have shown promising prospects in the treatment of cardiovascular disease.</description><subject>cardiovascular disease</subject><subject>histone deacetylase 6</subject><subject>inhibitor</subject><issn>2770-9191</issn><issn>2770-9183</issn><issn>2770-9183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kM1KAzEUhYMoVmrBJ5As3UzNnb8ky1LUFgqC6DpkMndKZDpTk7TSt_FZfDJTWuvK1bmL7x4OHyE3wMbAWHpvtE3HAPkZuUo5Z4kEkZ2fbgkDMvL-nUVUAgjBL8kgEzLnvOBX5GVmfeg7pDVqg2HXao-0_P7Snmra9Vts6dr1K-ttt6RBuyUGGnoaHOpAjXa17bfam02rHa2tx_h-TS4a3XocHXNI3h4fXqezZPH8NJ9OFolJ8zJPDDSayYxBVSIYxoq8aoxAHVNWQhYNz-oaqqYpJKsqrCAFwJKVArLSyJJnQ3J36I0DPzbog4ozDbat7rDfeJUxnkdWivwPNa733mGj1s6utNspYGovUe0lqigxorfH1k21wvoE_iqLQHIAPm2Lu3-L1HQyT_eFPwave0E</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Wu, Ya‐Xi</creator><creator>Li, Bing‐Qian</creator><creator>Yu, Xiao‐Qian</creator><creator>Liu, Yu‐Lin</creator><creator>Chui, Rui‐Hao</creator><creator>Sun, Kai</creator><creator>Geng, Dian‐Guang</creator><creator>Ma, Li‐Ying</creator><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7186-8259</orcidid></search><sort><creationdate>202406</creationdate><title>Histone deacetylase 6 as a novel promising target to treat cardiovascular disease</title><author>Wu, Ya‐Xi ; Li, Bing‐Qian ; Yu, Xiao‐Qian ; Liu, Yu‐Lin ; Chui, Rui‐Hao ; Sun, Kai ; Geng, Dian‐Guang ; Ma, Li‐Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2464-c1fa09301b6e1c0054bfc8ea54b9b895f73dd1bff590bbeb1211e6068136c9673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>cardiovascular disease</topic><topic>histone deacetylase 6</topic><topic>inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Ya‐Xi</creatorcontrib><creatorcontrib>Li, Bing‐Qian</creatorcontrib><creatorcontrib>Yu, Xiao‐Qian</creatorcontrib><creatorcontrib>Liu, Yu‐Lin</creatorcontrib><creatorcontrib>Chui, Rui‐Hao</creatorcontrib><creatorcontrib>Sun, Kai</creatorcontrib><creatorcontrib>Geng, Dian‐Guang</creatorcontrib><creatorcontrib>Ma, Li‐Ying</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer innovation (Print)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Ya‐Xi</au><au>Li, Bing‐Qian</au><au>Yu, Xiao‐Qian</au><au>Liu, Yu‐Lin</au><au>Chui, Rui‐Hao</au><au>Sun, Kai</au><au>Geng, Dian‐Guang</au><au>Ma, Li‐Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone deacetylase 6 as a novel promising target to treat cardiovascular disease</atitle><jtitle>Cancer innovation (Print)</jtitle><addtitle>Cancer Innov</addtitle><date>2024-06</date><risdate>2024</risdate><volume>3</volume><issue>3</issue><spage>e114</spage><epage>n/a</epage><pages>e114-n/a</pages><issn>2770-9191</issn><issn>2770-9183</issn><eissn>2770-9183</eissn><abstract>Histone deacetylase 6 (HDAC6) belongs to a class of epigenetic targets that have been found to be a key protein in the association between tumors and cardiovascular disease. Recent studies have focused on the crucial role of HDAC6 in regulating cardiovascular diseases such as atherosclerosis, myocardial infarction, myocardial hypertrophy, myocardial fibrosis, hypertension, pulmonary hypertension, and arrhythmia. Here, we review the association between HDAC6 and cardiovascular disease, the research progress of HDAC6 inhibitors in the treatment of cardiovascular disease, and discuss the feasibility of combining HDAC6 inhibitors with other therapeutic agents to treat cardiovascular disease.
HDAC6 have been found to be a key protein in the tumor–cardiovascular association. HDAC6 inhibitors may have important moderating effects in various types of cardiovascular diseases. HDAC6 inhibitors alone or in combination with other agents have shown promising prospects in the treatment of cardiovascular disease.</abstract><cop>England</cop><pmid>38947757</pmid><doi>10.1002/cai2.114</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-7186-8259</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2770-9191 |
| ispartof | Cancer innovation (Print), 2024-06, Vol.3 (3), p.e114-n/a |
| issn | 2770-9191 2770-9183 2770-9183 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3074136984 |
| source | DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | cardiovascular disease histone deacetylase 6 inhibitor |
| title | Histone deacetylase 6 as a novel promising target to treat cardiovascular disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T06%3A53%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20deacetylase%206%C2%A0as%20a%20novel%20promising%20target%20to%20treat%20cardiovascular%20disease&rft.jtitle=Cancer%20innovation%20(Print)&rft.au=Wu,%20Ya%E2%80%90Xi&rft.date=2024-06&rft.volume=3&rft.issue=3&rft.spage=e114&rft.epage=n/a&rft.pages=e114-n/a&rft.issn=2770-9191&rft.eissn=2770-9183&rft_id=info:doi/10.1002/cai2.114&rft_dat=%3Cproquest_cross%3E3074136984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3074136984&rft_id=info:pmid/38947757&rfr_iscdi=true |